View of Mickey Mouse at the entrance to Walt Disney World Theme Park on July 9, 2020 in the Lake Buena vista of Florida.
Octavio Jones | Getty Images
(This story is just for CNBC Pro subscribers)
With several Phase 3 Covid-19 vaccines and preliminary data earlier this month, Goldman Sachs is preparing its clients for a jump in certain stocks and recommends tweaking the client portfolio.
He is a U.S. citizen. Grouped some equity listings into four buckets.
The first bucket includes stocks that sold out in 2020, but people usually bounce back so should bounce back. “The second bucket includes equities that seem to have gained a competitive advantage but need to reinvest their markets.
The third is that we should bounce back when global growth improves. And the fourth bucket is the stock that should be well rented in the long run but will remain volatile in the near term, even if the vaccine is valid.
“Against this background of potential catalysts ahead, we pay no attention to when the vaccine for the virus will be approved. We are looking to identify a comparative shortlist of 19 stocks compared to our U.S. GIR coverage universe. Which our analysts believe will go a long way. “The vaccine has been approved,” wrote Goldman analyst Chris Hussey.
.
